Eribulin mesylate.

  title={Eribulin mesylate.},
  author={Sarika Jain and Linda T. Vahdat},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={17 21},
Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the U.S. Food and Drug Administration as third-line treatment of metastatic breast cancer refractory to anthracyclines and taxanes. Eribulin is a synthetic analogue of halichondrin B, which inhibits microtubule polymerization by a mechanism distinct from other available antitubulin agents. Eribulin significantly increased overall survival (OS; median OS for the eribulin-treated group was 13… CONTINUE READING
11 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…